CN103025308B - 咖啡酰酒石酸及衍生物在食品补充剂中用于调节皮肤色素沉着的用途 - Google Patents
咖啡酰酒石酸及衍生物在食品补充剂中用于调节皮肤色素沉着的用途 Download PDFInfo
- Publication number
- CN103025308B CN103025308B CN201180030751.2A CN201180030751A CN103025308B CN 103025308 B CN103025308 B CN 103025308B CN 201180030751 A CN201180030751 A CN 201180030751A CN 103025308 B CN103025308 B CN 103025308B
- Authority
- CN
- China
- Prior art keywords
- skin
- extract
- application described
- caftaric acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SWGKAHCIOQPKFW-JTNORFRNSA-N Caftaric acid Chemical compound OC(=O)[C@H](O)[C@H](C(O)=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 SWGKAHCIOQPKFW-JTNORFRNSA-N 0.000 title claims abstract description 37
- SWGKAHCIOQPKFW-GHMZBOCLSA-N caffeoyltartaric acid Natural products OC(=O)[C@H](O)[C@H](C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 SWGKAHCIOQPKFW-GHMZBOCLSA-N 0.000 title claims abstract description 34
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 7
- 208000012641 Pigmentation disease Diseases 0.000 title description 7
- 230000019612 pigmentation Effects 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 239000002537 cosmetic Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims description 48
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 244000298479 Cichorium intybus Species 0.000 claims description 21
- 230000003213 activating effect Effects 0.000 claims description 13
- 241000723343 Cichorium Species 0.000 claims description 10
- 230000008591 skin barrier function Effects 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 208000031019 skin pigmentation disease Diseases 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000000638 solvent extraction Methods 0.000 claims description 5
- 230000001629 suppression Effects 0.000 claims description 5
- 230000002087 whitening effect Effects 0.000 claims description 5
- 208000003351 Melanosis Diseases 0.000 claims description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 4
- 240000006365 Vitis vinifera Species 0.000 claims description 4
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 4
- 230000003796 beauty Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 240000008415 Lactuca sativa Species 0.000 claims description 3
- 235000003228 Lactuca sativa Nutrition 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 206010008570 Chloasma Diseases 0.000 claims description 2
- 240000001949 Taraxacum officinale Species 0.000 claims description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 2
- -1 acyl tartaric acid Chemical compound 0.000 claims description 2
- 230000002605 anti-dotal effect Effects 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 229940126701 oral medication Drugs 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 230000000529 probiotic effect Effects 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims 8
- 230000037213 diet Effects 0.000 claims 8
- 230000009469 supplementation Effects 0.000 claims 8
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000003809 water extraction Methods 0.000 claims 1
- 235000020795 whole food diet Nutrition 0.000 claims 1
- 239000000049 pigment Substances 0.000 abstract description 10
- 208000017520 skin disease Diseases 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 3
- 208000000069 hyperpigmentation Diseases 0.000 abstract description 3
- 230000003810 hyperpigmentation Effects 0.000 abstract description 3
- 239000007854 depigmenting agent Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 42
- 230000000694 effects Effects 0.000 description 15
- 102000003425 Tyrosinase Human genes 0.000 description 14
- 108060008724 Tyrosinase Proteins 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000008569 process Effects 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000005418 vegetable material Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 108010076039 Polyproteins Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005238 degreasing Methods 0.000 description 5
- 210000002752 melanocyte Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 4
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 4
- 229960004705 kojic acid Drugs 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007940 sugar coated tablet Substances 0.000 description 3
- 108700034262 4-Nle-7-Phe-alpha- MSH Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- UAHFGYDRQSXQEB-LEBBXHLNSA-N afamelanotide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 UAHFGYDRQSXQEB-LEBBXHLNSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000009442 piebaldism Diseases 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000522254 Cassia Species 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001166194 Geranium wilfordii Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 206010024648 Livedo reticularis Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical group C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 1
- 229930016920 cichoric acid Natural products 0.000 description 1
- 235000006193 cichoric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明总的涉及用于美容目的的食品补充剂和/或食物产品领域。更具体地讲,本发明旨在提供一种含有咖啡酰酒石酸和/或衍生物的成分,用于预防和/或治疗皮肤的过度色素沉着、皮肤色斑例如老人斑和特征在于色素异常的其它皮肤病症。本发明的目的还在于改善皮肤色调以及提供皮肤美白剂。
Description
本发明总的涉及用于美容目的的食品补充剂领域。更具体地讲,本发明旨在提供一种含有咖啡酰酒石酸和/或衍生物的成分,用于预防和/或治疗皮肤的过度色素沉着、皮肤色斑例如老人斑和特征在于色素异常的其它皮肤病症。本发明的目的还在于改善皮肤色调以及提供皮肤美白或增白剂。
发明背景
皮肤颜色主要是由存在于皮肤中的一种棕色色素――黑色素的量和类型决定的。黑色素的量越少皮肤越白,量越多皮肤颜色越深。此外,皮肤的过度色素沉着也是由皮肤中黑色素的过度表达或积聚造成的。因此,黑色素产生所涉及的途径已经成为许多用来降低黑色素产生水平的抑制剂的靶点。在黑色素途径中所涉及的主要的酶之一是酪氨酸酶。
黑色素的合成是一个受激素控制的过程,包括由前体阿黑皮素原产生的促黑素細胞激素(MSH)和促肾上腺皮质激素(ACTH)肽。由UVB照射所引起的DNA损伤可以刺激该过程。
因此,长时间的日晒会引起皮肤中的许多生化反应,导致例如皮肤晒黑和晒成褐色。日晒的其它后果会随着时间而累积。这些变化可以引起老人斑的出现并产生不均匀的、斑驳的皮肤色调。不幸的是,目前在市场上可购买到的许多产品要么仅有很弱的效果,要么含有不稳定的活性成分,这些成分在掺入最终的配方中时会失去它们的效力。
在当今社会,非常希望能够改变皮肤中色素的表达量,以促进均匀或美白的肤色。许多人希望改变他们的肤色、减少老人斑等,或者是为了纯粹的美容原因。
其结果是,开发有效组合物的尝试都集中在了抑制酪氨酸酶活性的物质上。例如,已提出将各种酪氨酸酶抑制剂例如氢醌、维生素C、半胱氨酸、曲酸、熊果苷和谷胱甘肽等用于局部组合物中。此外,也有人提出将多种皮肤病学组合物用于改善色素异常(例如在黄褐斑、雀斑、白癜风、斑驳病、苯丙酮尿症等中所观察到的那些)的面貌和/或用于美容目的。
此外,皮肤漂白组合物的使用也被广泛延伸。然而,它们或者破坏黑色素,或者是抑制其形成。许多这样的组合物含有苛性化学物质,例如过氧化物、酸或甲醛,或硫醇化的物质。不太苛性的疗法具有其它缺点。
有人提出使用局部类视色素和局部皮质甾类作为色素减轻剂,还有人提出了激光疗法和化学去皮法,但这些方法的缺点是无法获得所需的响应。
其它一些组合物提出在皮肤上使用天然物质,其中有些天然物质已经在亚洲或欧洲使用了数个世纪,用来漂白皮肤和皮肤区域,或用于增强白皙皮肤的美感。其中包括使用柠檬、橙、黄瓜、银杏、长豆角、玫瑰果、老鹳草、肉桂、马郁兰、迷迭香等。
为了对抗与异常色素有关的病症或者为了美白肤色,已提出使用各种当局部涂抹在皮肤上时能够降低酪氨酸酶活性并因此限制黑色素产生的化合物。不幸的是,目前可以采用的处置方法不能完全令人满意,特别是在经常伴随的副作用方面,例如某些局部活性剂的刺激性副作用。
因此,非常希望不存在现有技术中所记载的那些缺点的其它可替代的制剂。具体地讲,非常希望开发出用于通过口服途径施用的营养性美容组合物,其具有改善的稳定性和促进均匀肤色或美白肤色的效力。
此外,还需要对于治疗和/或预防皮肤色素沉着异常、特别是由于环境因素或衰老所引起的那些异常有效的活性剂。
本发明的目的满足了这些需求。
发明概述
本发明人可以通过提供含有至少一种包含咖啡酰酒石酸和/或衍生物的成分的食品补充剂组合物实现该目的。
因此,本发明的第一个主题涉及有效量的至少一种包含菊苣酸和/或衍生物的成分作为活性剂用于治疗和/或预防皮肤色素沉着异常的美容应用。所述皮肤病症特别是那些由于年龄或环境(例如紫外线)因素引起的异常,例如老人斑。其还可以是在黄褐斑、雀斑、白癜风、斑驳病、苯丙酮尿症等中所观察到的那些。
本发明人发现,咖啡酰酒石酸及衍生物可以有效抑制黑色素的形成(黑素生成),尽管事实上该提取物对酪氨酸酶的活性的抑制很弱或没有抑制。考虑到酪氨酸酶在黑素生成中的关键作用以及现有技术中的开发尝试都集中在对该酶的抑制上,该结果是令人惊奇并且出人意料的。
对于本发明的目的而言,术语“皮肤”是指面部或身体的皮肤。
对于本发明的目的而言,术语“有效量”是指足以获得预期效果的量。
对于本发明的目的而言,术语“预防”是指降低所考虑的异常/病症的迹象出现的危险性。
本发明还涉及上述成分作为活性剂用于治疗和/或预防皮肤色斑的美容应用。其结果是,肤色变得更亮更均匀,没有皮肤变色或干燥的区域。
本发明还涉及有效量的至少一种含有本发明的咖啡酰酒石酸和/或衍生物的成分作为活性剂用于增白或美白皮肤色调的美容应用。
本发明人还发现,本发明的成分可以进一步改善皮肤含水量和/或皮肤屏障功能。
本发明的应用还包括至少一种包含咖啡酰酒石酸和/或衍生物的成分与有效量的至少一种用于进一步改善皮肤含水量或皮肤老化的活性剂、特别是下述的那些活性剂的组合应用。
另一方面,本发明的主题涉及在个体中治疗和/或预防皮肤色斑以及与过度色素沉着有关的病症、特别是美学上的病症的方法、特别是美容方法,该方法包括至少一个向所述个体施用至少一种包含本发明的咖啡酰酒石酸和/或衍生物的成分的步骤。
本发明的组合物可以口服给药。其优点是可以通过迅速并且相对无限制性的给药方式全身作用于整个皮肤的深层(真皮、下皮)。具体地讲,代谢物及其它活性营养物质通过血流的作用特别分布于皮肤基质内。口服给药还具有迅速和相对无限制性给药方式的优点。
发明详述
包含咖啡酰酒石酸和/或衍生物的成分
咖啡酰酒石酸是
其衍生物包括在OH-基团和/或CO2H-基团上显示至少一个C1-C3烷基化的化合物。例如,两个酚OH-基团均可以被烷基化。二者择一地和/或额外地,两个羧基基团可以被转化成相应的烷基酯。在一个实施方案中,所有的OH-基团和所有的CO2H-基团均被烷基化。
典型的衍生物是其中两个酚OH-基团均被甲基化的化合物,和/或其中两个羧基基团均被甲基化的化合物。
其它典型的衍生物包括具有下式的化合物
其中R1和/或R2选自H;CH3;芳基,例如苯基、苄基、甲苯基、邻二甲苯基烷基;C1-C3-酰基、氨基酸、单糖。R1和/或R2可以相同或者可以彼此不同。
一种咖啡酰酒石酸衍生物是如下化合物:
包含咖啡酰酒石酸和/或其衍生物的成分可以是包含咖啡酰酒石酸和/或其衍生物的任何成分,其可以是天然的或是另外添加的形式,但优选天然的食品例如莴苣、菊苣、蒲公英、葡萄、葡萄皮渣;或其组合或提取物。
在一个优选的实施方案中,植物材料是菊苣或其提取物的形式。菊苣提取物可以从植物材料的任何适宜部分制得,包括,例如根、果肉等,或其组合。
用于本发明目的的适宜的菊苣提取物还可以是可购买到的提取物,例如LerouxMS55(可购自Leroux SAS,法国)。
在一个特别优选的本发明实施方案中,适宜的菊苣提取物可以通过本领域已知的任何方法制备,例如,通过蒸汽提取、溶剂提取、蒸馏、挤压或研磨来制备。具体地讲,提取物可以通过用溶剂从菊苣植物材料提取,通过水提取或醇/水提取,例如通过乙醇/水提取或甲醇/水提取获得。提取物可以以液体的形式(例如Leroux MS55,Leroux MS70)或以粉末的形式(例如Leroux Sol B)使用。
为了便于操作,植物材料优选是干燥并且是粉碎或粉末的形式。如下所述,加工过程使用干燥、粉碎的菊苣和/或其提取物。但是,应当理解,可以以任何适宜的形式使用任何适宜的植物材料并将其加入到本发明的产物中。
对提取物进行加工从而使其风味可以提高。例如,可以通过将植物加工成提取物来去除植物材料例如菊苣通常带有的苦味。还可以制备提取物以使最终的提取物产品中生物活性剂的量可以被理想地控制。
应当理解,可以以多种不同的适宜方式将植物材料加工成提取物。通常,将植物材料例如菊苣根碾碎、制成粉末或以任何适宜的形式提供。然后可以将植物材料在多个不同的阶段进一步加工以生成产品提取物。在一个实施方案中,对植物材料进行脱脂工艺以生产由去除了脂肪的植物材料制得的提取物。脱脂工艺可以在任何适宜的脱脂加工条件下用任何适宜类型和数量的溶剂、包括例如己烷进行。
在一个实施方案中,由脱脂工艺制得的提取物可以进一步通过酸水解进行加工,以生产可以加入到本发明的营养组合物中的另一种类型的植物提取物。酸水解工艺可以在任何适宜的加工条件下使用任何适宜类型和数量的溶剂、包括例如乙酸乙酯进行。
在一个实施方案中,由脱脂工艺制得的提取物可以进一步通过溶剂提取工艺进行加工。溶剂提取可以在任何适宜的加工条件下在任何适宜量和类型的溶剂存在下进行。在一个实施方案中,溶剂包括甲醇("MeOH")和水以1:1的体积比混合的溶液。由溶剂提取工艺得到的溶液可以通过在适宜条件下蒸发溶剂进行进一步加工,以生产另一种提取物。或者,可将得到的溶液用吸附剂例如聚乙烯聚吡咯烷酮等处理,以捕获多酚。吸附剂处理可以在任何适宜的加工条件下进行。
产品中咖啡酰酒石酸和/或其天然来源的量取决于许多因素,例如提取物的性质、植物的情况、待治疗的人或动物的年龄、状况和个头大小、产品准备施用的频率和/或待治疗或预防的皮肤病症或损伤的具体类型或所需的美容效果。
本发明人发现,本发明的菊苣或其提取物的效力通常是剂量依赖型的并且遵循剂量响应曲线。如果需要预防的是轻微的皮肤病症或损伤并且产品将频繁地使用,则非常少量的菊苣或其提取物就将足以获得所需的效果。如果需要治疗的是严重的皮肤色素异常,更大量的菊苣或其提取物将是更适宜的,尽管小的量也会产生效果。
通常,成分中富含咖啡酰酒石酸和/或其衍生物是优选的。例如,成分和/或组合物中可以包含含量范围为干重的0.001-99.99重量%,优选干重的0.1-50重量%,最优选干重的0.1-10重量%的咖啡酰酒石酸和/或其衍生物。成分和/或组合物可以包含含量范围为干重的0.001-99.99重量,优选干重的0.1-50重量%,最优选干重的0.1-10重量%的能够水解咖啡酰酒石酸和/或其衍生物以生成酒石酸和/或咖啡酸的乳酸菌。
在另一个实施方案中,在产品中包含含量范围为约0.1g/l至10g/l,优选0.5g/l至3g/l产品的菊苣或其提取物。如果产品的总量不能以升计,则优选在产品中包含含量范围为约0.1g/kg至10g/kg,优选0.5g/kg至3g/kg产品的菊苣或其提取物。
优选在产品中包含每日剂量为0.01g-100g,优选0.25g-10g的菊苣或其提取物。
本发明的组合物可以是任何通常适用于所选择的施用方法的盖仑制剂形式。
口服组合物
本发明的组合物可以是任何通常适用于所选择的施用方法的盖仑制剂形式。根据所考虑的组合物类型,载体可以具有不同的性质。
具体地讲,菊苣或其提取物可以掺入任何形式的食品补充剂中。
例如,其可以存在于胶囊、明胶胶囊、软胶囊、片剂、糖包衣片剂、丸剂、糊剂或锭剂、口香糖或可饮用的溶液或乳液、糖浆或凝胶中。所述补充剂还可以包含甜味剂、稳定剂、抗氧剂、添加剂、矫味剂和/或着色剂。其配制通过用于生产糖包衣片剂、明胶胶囊、凝胶、控释水凝胶、乳剂、片剂或胶囊的常用方法来进行。
应用
本发明的产品可以通过例如减少黑色素的生成有效地用于治疗或预防皮肤色素沉着异常或在美容上用于美白肤色等。确实,咖啡酰酒石酸及菊苣提取物显示出可以在体外减少黑色素的合成(实施例1,图1)。酪氨酸酶的生成也减少,但程度有限(图2),这表明黑色素的减少不是由于酪氨酸酶的抑制,而是由于作用于该酶的上游或下游的机制。
本发明的成分还对加固皮肤屏障以及皮肤保湿具有积极作用。
其结果是,色斑减少,肤色变得更亮更均匀,没有皮肤变色或干燥的区域。
因此,本发明的一个主题涉及有效量的至少一种包含咖啡酰酒石酸和/或衍生物的成分作为活性剂用于治疗和/或预防皮肤色素沉着异常,特别是由于年龄或环境因素例如紫外线引起的异常的美容应用。
本发明还涉及有效量的至少一种包含咖啡酰酒石酸和/或衍生物的成分作为活性剂用于增白或美白肤色的美容应用,这是亚洲人特别希望的。
本发明的应用还包括至少一种包含咖啡酰酒石酸和/或衍生物的成分与有效量的至少一种用于改善皮肤含水量或皮肤老化的活性剂、特别是下述的那些活性剂的组合应用。
另一方面,本发明的主题涉及在个体中治疗和/或预防皮肤色斑以及与过度色素沉着有关的病症、特别是美学上的病症的方法、特别是美容方法,该方法包括至少一个向所述个体施用至少一种本发明的包含咖啡酰酒石酸和/或衍生物的成分的步骤。
本发明的美容性治疗方法可以通过口服施用至少有效量的至少一种本发明的包含咖啡酰酒石酸和/或衍生物的成分来进行。口服施用包括一次或分多次摄入以上所定义的口服组合物。
其可以包括单次应用。根据另一个实施方案,应用可以每天重复例如2至3次或更多,并且通常持续至少4周或是1至15周。
此外,为了补充或强化本发明所定义的成分的活性,还可以考虑任选的与口服或局部形式的组合治疗。
因此,本发明的包含菊苣或其提取物的组合物与任选地含有另一种活性成分、特别是益生微生物或其它死亡、活的或半活形式的益生菌或保湿剂或抗衰老剂的口服或局部组合物组合的局部或口服治疗可以被看作是药盒。在配制前,将成分按照本领域技术人员很容易确定的顺序和条件进行混合。
在配制前,将成分按照本领域技术人员很容易确定的顺序和条件进行混合。
从以下的实施例和附图中可以明显看出本发明的其它优点和特征。因此,以下实施例用于以非限制性的方式说明本发明的领域。除非另有说明,在这些实施例中的百分比是重量百分比,以“…至…”写出的数值范围包括具体指明的上限和下限。
附图
图1:与对照相比,用咖啡酰酒石酸或菊苣提取物预处理的鼠黑素细胞的黑色素生成(阳性/阴性)。
图2:与对照相比,用咖啡酰酒石酸或菊苣提取物预处理的鼠黑素细胞的酪氨酸酶生成(阳性/阴性)。
图3:与对照相比,用咖啡酰酒石酸或菊苣提取物预处理的人原代表皮角质形成细胞的丝聚蛋白合成(阳性/阴性)。
实施例
实施例1:咖啡酰酒石酸对皮肤色素沉着的影响
为了评估成分对皮肤脱色或促进色素沉着的潜在有益作用,我们用鼠黑素细胞的2D培养物(B16)进行了2项试验:1-评估黑色素生成和2-评估酪氨酸酶生成。
1.细胞培养条件
将B16细胞在含有1g/L葡萄糖、不含酚红、补充有10%胎牛血清的DMEM中在增湿培养室中在37°C、含5%CO2的条件下培养。
2.由B16鼠黑素细胞系生成的黑色素
将细胞与选定的成分或试验参照物(曲酸,400μg/mL)一起在存在或不存在MSH的类似物NDP-MSH的条件下保温72小时。黑色素的总量(细胞外和细胞内的)通过在405nm下测定各样品与黑色素标准品相比在存在或不存在NDP-MSH条件下的光密度来评估。
3.由B16鼠黑素细胞系生成的酪氨酸酶
将细胞与选定的成分或试验参照物(曲酸,400μg/mL)一起保温48小时。
通过免疫标记法评估酪氨酸酶的生成。
成分
我们测试了两种菊苣提取物MS-55(concentréMS-55LEROUX)和MS-70(MS-70LEROUX)以及咖啡酰酒石酸。试验浓度如下表1所示。
结果
结果以相对于对照的百分比表示。正如所预期的,试验参照物(曲酸)引起了黑色素生成的减少。图1显示了用选定的成分处理72小时的B16黑素细胞所生成的黑色素。
咖啡酰酒石酸比测试的菊苣提取物MS-70更有效地在体外减少了黑色素生成(图1)。这些成分也使酪氨酸酶的生成减少,但程度有限(图2),这表明黑色素的减少不是由于酪氨酸酶的抑制,而是由于作用于该酶的上游或下游的机制。
实施例2:咖啡酰酒石酸对皮肤屏障功能和皮肤含水量的影响
使用人原代表皮角质形成细胞的2D培养物,通过评估丝聚蛋白的合成来评估实施例1的提取物对皮肤屏障功能和皮肤含水量的潜在有益作用。
细胞培养条件
将人表皮角质形成细胞在限制性角质形成细胞无血清培养基中在增湿培养室中在37°C、含5%CO2的条件下培养。
由人表皮角质形成细胞合成丝聚蛋白
将细胞与选定的成分或试验参照物(CaCl2,1.5mM)一起保温144小时。通过免疫标记法评估丝聚蛋白的生成。
结果
菊苣提取物MS-55和MS-70以及咖啡酰酒石酸均增加了丝聚蛋白的生成,这表明这些化合物对于加固皮肤屏障具有积极作用(图2)。较强的皮肤屏障可以更好地保护机体免受环境和病原体的攻击。其还限制了通过表皮的水分丢失,从而确保了适宜的皮肤含水量。
实施例3:粉棒(Powder stick)
成分 | 量 |
活性成分 | |
菊苣提取物MS-55 | 8g |
赋形剂 | |
麦芽糖糊精 | 适量至30g |
黄原胶 | 0.8mg |
苯甲酸钠 | 0.2mg |
可以每天食用一条粉棒。
该类型的糖包衣片剂可以每天服用1至3次。
Claims (19)
1.有效量的至少一种包含咖啡酰酒石酸和/或衍生物的成分作为活性剂在制备用于通过抑制黑色素形成来治疗和/或预防皮肤色素异常、改善皮肤含水量和改善皮肤屏障功能的口服食品补充剂中的美容应用,其中所述口服食品补充剂包含干重的0.1-50重量%的咖啡酰酒石酸,并且其中的咖啡酰酒石酸衍生物是在咖啡酰酒石酸的OH-基团和/或CO2H-基团上显示至少一个C1-C3烷基化的化合物。
2.权利要求1所述的应用,其特征在于所述皮肤色素异常是在黄褐斑、雀斑、白癜风、斑驳病、苯丙酮尿症中所观察到的那些和/或老人斑。
3.权利要求1所述的应用,其特征在于所述皮肤色素异常是皮肤色斑。
4.权利要求1所述的应用,用于改善皮肤色调和/或肤色。
5.有效量的至少一种包含咖啡酰酒石酸和/或衍生物的成分作为活性剂在制备用于通过抑制黑色素形成来美白皮肤色调、改善皮肤含水量和改善皮肤屏障功能的口服食品补充剂中的美容应用,其中所述口服食品补充剂包含干重的0.1-50重量%的咖啡酰酒石酸,并且其中的咖啡酰酒石酸衍生物是在咖啡酰酒石酸的OH-基团和/或CO2H-基团上显示至少一个C1-C3烷基化的化合物。
6.权利要求1-5之一所述的应用,其中包含咖啡酰酒石酸的成分是一种选自莴苣、菊苣、蒲公英、葡萄、葡萄皮渣的天然食品;或其组合或提取物。
7.权利要求6所述的应用,其中的提取物是通过溶剂提取从菊苣植物材料获得的。
8.权利要求7所述的应用,其中的提取物是通过水提取或醇/水提取获得的。
9.权利要求8所述的应用,其中的提取物是通过乙醇/水提取获得的。
10.权利要求1-5之一所述的应用,其中所述口服食品补充剂中菊苣或其提取物的含量在0.1g/l至10g/l的范围内。
11.权利要求10所述的应用,其中所述口服食品补充剂中菊苣或其提取物的含量在0.5g/l至3g/l的范围内。
12.权利要求1-5之一所述的应用,其中所述口服食品补充剂含有日剂量为0.01g-100g的菊苣或其提取物。
13.权利要求12所述的应用,其中所述口服食品补充剂含有日剂量为0.25g-10g的菊苣或其提取物。
14.权利要求1-5之一所述的应用,其中所述口服食品补充剂还含有至少一种死亡、活的或半活形式的食品级的益生菌。
15.权利要求1-5之一所述的应用,与有效量的至少一种用于改善皮肤含水量或皮肤老化的活性剂组合应用。
16.用于由于年龄引起的皮肤色素异常、改善皮肤含水量和改善皮肤屏障功能的非治疗性的美容方法,所述方法包括至少一个向个体口服施用有效量的菊苣或其提取物的步骤。
17.权利要求16所述的美容方法,其特征在于所述皮肤色素异常是皮肤色斑。
18.用于治疗和/或预防皮肤色素异常、改善皮肤含水量和改善皮肤屏障功能的药盒,所述药盒包括用含有菊苣或其提取物的食品补充剂的口服治疗,与含有死亡、活的或半活形式的益生菌微生物或保湿剂或抗衰老剂的局部组合物的组合。
19.权利要求18所述的药盒,其特征在于所述皮肤色素异常是皮肤色斑。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10167885.2 | 2010-06-30 | ||
EP10167885 | 2010-06-30 | ||
PCT/EP2011/060766 WO2012000961A1 (en) | 2010-06-30 | 2011-06-28 | Use of caftaric acid and derivatives in food supplement for regulating skin pigmentation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103025308A CN103025308A (zh) | 2013-04-03 |
CN103025308B true CN103025308B (zh) | 2017-04-05 |
Family
ID=43221976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180030751.2A Expired - Fee Related CN103025308B (zh) | 2010-06-30 | 2011-06-28 | 咖啡酰酒石酸及衍生物在食品补充剂中用于调节皮肤色素沉着的用途 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9492365B2 (zh) |
EP (1) | EP2588069B1 (zh) |
JP (1) | JP2013530996A (zh) |
KR (1) | KR20130111964A (zh) |
CN (1) | CN103025308B (zh) |
BR (1) | BR112012033090B1 (zh) |
CA (1) | CA2803461C (zh) |
ES (1) | ES2739049T3 (zh) |
MX (1) | MX349208B (zh) |
RU (1) | RU2012155854A (zh) |
SG (2) | SG186804A1 (zh) |
WO (2) | WO2012000955A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6595195B2 (ja) * | 2014-03-31 | 2019-10-23 | 日本メナード化粧品株式会社 | 特定の波長域を有する光を照射して栽培したチコリの抽出物を含有する皮膚外用剤や内用剤 |
WO2017173241A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
CA3043748A1 (en) | 2016-11-23 | 2018-05-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
TW202346276A (zh) * | 2022-01-27 | 2023-12-01 | 日商田邊三菱製藥股份有限公司 | 新穎之b0at1抑制劑 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102333459A (zh) * | 2009-01-27 | 2012-01-25 | 雀巢产品技术援助有限公司 | 包含咖啡酰酒石酸和/或其衍生物的组合物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2591073B1 (fr) * | 1985-12-10 | 1988-02-19 | Leroux Sarl Chicoree | Boisson a base de chicoree et procede de preparation de ladite boisson |
FR2653336B1 (fr) * | 1989-10-20 | 1994-04-08 | Oreal | Composition pharmaceutique et cosmetiques depigmentantes a base d'acide cafeique. |
JP3140876B2 (ja) * | 1993-01-27 | 2001-03-05 | ポーラ化成工業株式会社 | メラニン産生抑制剤及び皮膚外用剤 |
KR20000034037A (ko) | 1998-11-27 | 2000-06-15 | 박인배 | 티로시나제 저해제로서의 포도씨 추출물 |
JP4709459B2 (ja) * | 2000-03-06 | 2011-06-22 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 美容組成物中の抗刺激および抗老化増強物質としてのエキナセア抽出物 |
EP1260212A1 (de) | 2001-05-21 | 2002-11-27 | Cognis France S.A. | Kosmetische Mittel |
KR100970544B1 (ko) * | 2002-11-07 | 2010-07-16 | 코세 코퍼레이션 | 피부외용제용 조성물 및 그의 사용방법 |
JP2005194246A (ja) * | 2004-01-09 | 2005-07-21 | Ichimaru Pharcos Co Ltd | NF−κB活性化抑制剤 |
US7226623B2 (en) * | 2005-10-31 | 2007-06-05 | Rutgers, The State University Of New Jersey | In vitro and in vivo anti-inflammatory effects of a sesquiterpene lactone extract from chicory (Cichorium intybus L.) |
FR2892923B1 (fr) * | 2005-11-08 | 2009-01-16 | Engelhard Lyon Sa | Utilisatiion des derives de l'acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques. |
JP2008231002A (ja) * | 2007-03-19 | 2008-10-02 | Ina Food Ind Co Ltd | 抗酸化剤及びラジカル消去活性化剤、並びにそれらいずれかが含まれた食品 |
EP2210504A1 (en) * | 2009-01-27 | 2010-07-28 | Nestec S.A. | Composition comprising chicoric acid and/or derivatives thereof |
-
2011
- 2011-06-28 EP EP11727487.8A patent/EP2588069B1/en not_active Not-in-force
- 2011-06-28 SG SG2012094827A patent/SG186804A1/en unknown
- 2011-06-28 CA CA2803461A patent/CA2803461C/en not_active Expired - Fee Related
- 2011-06-28 RU RU2012155854/15A patent/RU2012155854A/ru not_active Application Discontinuation
- 2011-06-28 SG SG10201505156QA patent/SG10201505156QA/en unknown
- 2011-06-28 MX MX2012015234A patent/MX349208B/es active IP Right Grant
- 2011-06-28 ES ES11727487T patent/ES2739049T3/es active Active
- 2011-06-28 WO PCT/EP2011/060760 patent/WO2012000955A1/en active Application Filing
- 2011-06-28 US US13/805,897 patent/US9492365B2/en active Active
- 2011-06-28 CN CN201180030751.2A patent/CN103025308B/zh not_active Expired - Fee Related
- 2011-06-28 KR KR1020127033431A patent/KR20130111964A/ko active Search and Examination
- 2011-06-28 BR BR112012033090-0A patent/BR112012033090B1/pt not_active IP Right Cessation
- 2011-06-28 JP JP2013517238A patent/JP2013530996A/ja active Pending
- 2011-06-28 WO PCT/EP2011/060766 patent/WO2012000961A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102333459A (zh) * | 2009-01-27 | 2012-01-25 | 雀巢产品技术援助有限公司 | 包含咖啡酰酒石酸和/或其衍生物的组合物 |
Non-Patent Citations (1)
Title |
---|
紫锥菊属植物的化学成分、药理及开发利用研究进展;王康才等;《中药材》;20001231;第23卷(第12期);第780-782页 * |
Also Published As
Publication number | Publication date |
---|---|
US9492365B2 (en) | 2016-11-15 |
EP2588069A1 (en) | 2013-05-08 |
JP2013530996A (ja) | 2013-08-01 |
SG10201505156QA (en) | 2015-08-28 |
CN103025308A (zh) | 2013-04-03 |
MX2012015234A (es) | 2013-02-15 |
KR20130111964A (ko) | 2013-10-11 |
CA2803461A1 (en) | 2012-01-05 |
WO2012000961A1 (en) | 2012-01-05 |
MX349208B (es) | 2017-07-18 |
BR112012033090A2 (pt) | 2016-08-30 |
WO2012000955A1 (en) | 2012-01-05 |
ES2739049T3 (es) | 2020-01-28 |
US20130101556A1 (en) | 2013-04-25 |
CA2803461C (en) | 2018-09-25 |
SG186804A1 (en) | 2013-02-28 |
BR112012033090B1 (pt) | 2018-11-06 |
WO2012000961A9 (en) | 2012-02-23 |
RU2012155854A (ru) | 2014-06-27 |
EP2588069B1 (en) | 2019-05-15 |
CN102958500A (zh) | 2013-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103025307B (zh) | 菊苣酸及衍生物用于调节皮肤色素沉着的用途 | |
CN103025308B (zh) | 咖啡酰酒石酸及衍生物在食品补充剂中用于调节皮肤色素沉着的用途 | |
KR20090080153A (ko) | 피부 주름개선 또는 피부 미백용 조성물 | |
CN103079525A (zh) | 生咖啡豆用于调节皮肤色素沉着病症的用途 | |
CN103025309B (zh) | 菊苣酸和乳酸菌在食品补充剂中用于调节皮肤色素沉着的用途 | |
KR102024628B1 (ko) | 발아콩 추출물을 포함하는 미백용 또는 탈모 방지용 조성물 | |
WO2019098352A1 (ja) | 美容組成物、スクリーニング方法及び美容方法 | |
CN103068360B (zh) | 烘焙咖啡豆和生咖啡豆的混合物用于调节皮肤色素沉着的用途 | |
JP2011178770A (ja) | 皮膚の色素沈着を抑制する組成物およびその利用 | |
KR102343112B1 (ko) | 기능성 펩타이드, 아미노산, 캘러스 추출물 및 발효물을 포함하는 항노화 조성물 | |
CN102985058B (zh) | 咖啡酰酒石酸和乳酸菌在食品补充剂中用于调节皮肤色素沉着的用途 | |
KR102053994B1 (ko) | 흰점박이꽃무지유충의 추출물을 유효성분으로 포함하는 피부 미백 및 보습용 화장료 조성물 | |
JP2013256448A (ja) | 美白剤 | |
CN102958500B (zh) | 咖啡酰酒石酸及衍生物在食品或饮料中用于调节皮肤色素沉着的用途 | |
KR102286969B1 (ko) | 정제어유 유래 오메가-7 및 홍삼을 포함하는 피부 상태 개선용 조성물 | |
KR20110013238A (ko) | 멜라닌 생산 억제제 및 미백제 | |
CN106137816A (zh) | 一种落葵萃取物及其用途 | |
JP2013253020A (ja) | 美白剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200228 Address after: Vevey Co-patentee after: L'OREAL Patentee after: Societe des Produits Nestle S.A. Address before: Vevey Co-patentee before: L'OREAL Patentee before: NESTEC S.A. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170405 Termination date: 20210628 |